FDA Approves Bone-Softening Disorder Treatment CrysvitaApprovals, FDA/Regulatory, Priority Review, Rare Diseases, Rare Tumors, Tumor-Induced Osteomalacia (TIO)The U.S. Food and Drug Administration approved Crysvita (burosumab) for the treatment of a rare disease, tumor-induced osteomalacia. Read more June 19, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/06/FDA-Approves-Bone-Softening-Disorder-Treatment-Crysvita-BioSpace-6-19-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-06-19 12:50:552020-06-20 19:08:39FDA Approves Bone-Softening Disorder Treatment Crysvita